Pet Iq, Inc. PETQ
We take great care to ensure that the data presented and summarized in this overview for PetIQ, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PETQ
View all-
Black Rock Inc. New York, NY3.01MShares$93.2 Million0.0% of portfolio
-
Glazer Capital, LLC New York, NY2.19MShares$67.8 Million3.93% of portfolio
-
Eos Management, L.P.1.97MShares$61.1 Million21.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.56MShares$48.3 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.19MShares$36.8 Million0.03% of portfolio
-
Fil LTD Hamilton, D01.19MShares$36.8 Million0.04% of portfolio
-
Goldman Sachs Group Inc New York, NY1.17MShares$36.2 Million0.01% of portfolio
-
First Trust Capital Management L.P. Chicago, IL951KShares$29.5 Million3.38% of portfolio
-
Highland Capital Management Fund Advisors, L.P. Dallas, TX776KShares$24 Million2.82% of portfolio
-
Woodline Partners LP San Francisco, CA680KShares$21.1 Million0.19% of portfolio
Latest Institutional Activity in PETQ
Top Purchases
Top Sells
About PETQ
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Insider Transactions at PETQ
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 25
2024
|
Scott Huff Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,077
-100.0%
|
-
|
Oct 25
2024
|
Zvi Glasman Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
16,000
-100.0%
|
-
|
Oct 25
2024
|
Zvi Glasman Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,800
-100.0%
|
-
|
Oct 25
2024
|
Chad D. Lyon EVP Manufacturing & Sup. Chain |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
178
-100.0%
|
-
|
Oct 25
2024
|
Chad D. Lyon EVP Manufacturing & Sup. Chain |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,481
-100.0%
|
-
|
Oct 25
2024
|
William J. Carter EVP, GENERAL COUNSEL |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,497
-100.0%
|
-
|
Oct 25
2024
|
Mark L First Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,972,687
-100.0%
|
-
|
Oct 25
2024
|
Mark L First Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,547
-100.0%
|
-
|
Oct 25
2024
|
Michael A Smith PRESIDENT & COO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
88,808
-100.0%
|
-
|
Oct 25
2024
|
Sheryl Oloughlin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,822
-100.0%
|
-
|
Oct 25
2024
|
Mc Cord Christensen Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
114,027
-100.0%
|
-
|
Oct 25
2024
|
Mc Cord Christensen Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
145,675
-100.0%
|
-
|
Oct 25
2024
|
Mc Cord Christensen Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
114,027
+50.0%
|
-
|
Oct 25
2024
|
Kimberly Lefko Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,822
-100.0%
|
-
|
Oct 25
2024
|
Kenneth C. Walker Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,363
-100.0%
|
-
|
Oct 25
2024
|
John Paul Pearson EVP, SERVICES & MANUFACTURED |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,269
-100.0%
|
-
|
Oct 25
2024
|
Allan Hall Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,807
-100.0%
|
-
|
Oct 01
2024
|
John Paul Pearson EVP, SERVICES & MANUFACTURED |
SELL
Bona fide gift
|
Direct |
9,675
-59.21%
|
-
|
Aug 28
2024
|
William J. Carter EVP, GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
1,503
-30.06%
|
$45,090
$30.48 P/Share
|
Aug 28
2024
|
William J. Carter EVP, GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 242K shares |
---|---|
Conversion of derivative security | 114K shares |
Sale (or disposition) back to the issuer | 2.45M shares |
---|---|
Open market or private sale | 12.1K shares |
Payment of exercise price or tax liability | 85.8K shares |
Bona fide gift | 24.1K shares |